Sacituzumab Govitecan as a Treatment Option for Patients with metastatic triple-negative Breast Cancer and impending Liver Failure: two Case Reports

被引：0
|
作者：
Wolf, E. E. [1 ]
Agabejli, S. [1 ]
Wimberger, P. [1 ]
Link, T. [1 ]
机构：
[1] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Inst Abt Gynakol & Geburtshilfe, Dresden, Germany
来源：
GEBURTSHILFE UND FRAUENHEILKUNDE | 2023年 / 83卷 / 06期
关键词：
D O I：
10.1055/s-0043-1769875
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
66
引用
收藏
页码：E34 / E34
页数：1
相关论文
共 50 条
  • [31] Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore
    Cher, Boon Piang
    Goh, Sharon
    Aziz, Mohamed Ismail Abdul
    Wong, Grace
    Hui, Raymond Ng Chee
    Ong, Benjamin Shao-Kiat
    Ng, Kwong-Hoe
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (02) : 217 - 225
  • [32] Considerable Improvement in Overall Survival through Sacituzumab-Govitecan in metastatic triple-negative Breast Cancer
    Pervan, Mascha
    Krawczyk, Natalia
    Hanker, Lars
    Bundgen, Nana
    Rody, Achim
    Banys-Paluchowski, M.
    ONKOLOGE, 2021, 27 (11): : 1131 - 1136
  • [33] New drug approval: Sacituzumab govitecan in third line in advanced or metastatic triple-negative breast cancer
    Kabirian, Rayan
    Da Silva, Angelique
    BULLETIN DU CANCER, 2022, 109 (03) : 249 - 250
  • [34] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer
    Lang, Yitian
    Chai, Qingqing
    Tao, Wenqi
    Liao, Yahui
    Liu, Xiaoyan
    Wu, Bin
    BREAST, 2023, 68 : 173 - 180
  • [35] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
    Jiao Xie
    SiNi Li
    YaMin Li
    JianHe Li
    BMC Health Services Research, 23
  • [36] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
    Xie, Jiao
    Li, SiNi
    Li, YaMin
    Li, JianHe
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [37] COST-EFFECTIVENESS ANALYSIS OF SACITUZUMAB GOVITECAN AS SECOND-LINE TREATMENT FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER IN JAPAN
    Yamaguchi, M.
    Maeda, T.
    Morimoto, K.
    Chen, W.
    Moriwaki, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2023, 26 (06) : S106 - S106
  • [38] Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer—phase 3 ASCENT study subanalysis
    Lisa A. Carey
    Delphine Loirat
    Kevin Punie
    Aditya Bardia
    Véronique Diéras
    Florence Dalenc
    Jennifer R. Diamond
    Christel Fontaine
    Grace Wang
    Hope S. Rugo
    Sara A. Hurvitz
    Kevin Kalinsky
    Joyce O’Shaughnessy
    Sibylle Loibl
    Luca Gianni
    Martine Piccart
    Yanni Zhu
    Rosemary Delaney
    See Phan
    Javier Cortés
    npj Breast Cancer, 8
  • [39] Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
    Rugo, Hope S.
    Tolaney, Sara M.
    Loirat, Delphine
    Punie, Kevin
    Bardia, Aditya
    Hurvitz, Sara A.
    O'Shaughnessy, Joyce
    Cortes, Javier
    Dieras, Veronique
    Carey, Lisa A.
    Gianni, Luca
    Piccart, Martine J.
    Loibl, Sibylle
    Goldenberg, David M.
    Hong, Quan
    Olivo, Martin
    Itri, Loretta M.
    Kalinsky, Kevin
    NPJ BREAST CANCER, 2022, 8 (01)
  • [40] Pharmacokinetics (PK) of sacituzumab govitecan (SG) in patients (Pts) with metastatic triple-negative breast cancer (mTNBC) and other solid tumors
    Sathe, A. G.
    Singh, I.
    Singh, P.
    Diderichsen, P.
    Wang, X.
    Chang, P.
    Phan, S-C.
    Girish, S.
    Othman, A. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S214 - S214
12345